<DOC>
	<DOC>NCT02790710</DOC>
	<brief_summary>The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.</brief_summary>
	<brief_title>Brief Intervention for OCD Fears</brief_title>
	<detailed_description>Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear reactivation procedure. Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention</detailed_description>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Principal Diagnosis of ObsessiveCompulsive Disorder History of other serious psychiatric disorder Current Major Depressive Disorder Women who are pregnant or nursing Current use of psychiatric medication Persons planning to start another treatment during the study period Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>propanolol</keyword>
	<keyword>obsessive-compulsive disorder</keyword>
</DOC>